A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma.
Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Emese Zsíros, Bradley J. Monk(Florida Cancer Specialists & Research Institute), David M. O’Malley(The Ohio State University), Brian M. Slomovitz(Mount Sinai Medical Center), Robert M. Wenham(Moffitt Cancer Center), Gini F. Fleming(University of Chicago Medical Center), Maria Fardis(Pharmacyclics (United States)), Robert P. Edwards(Cancer Research UK Technology), Igor Gorbatchevsky(Theravance Biopharma (United States)), Robert J. Brown(Aduro BioTech (United States)), Samuel Suzuki(Theravance Biopharma (United States)), Koji Matsuo(University of Southern California)
Cited by 4
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k